Original Article

You have full text access to this OnlineOpen article

Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection

  1. Kimberly M. Rieger-Christ Ph.D.1,†,
  2. Arthur Mourtzinos M.D.2,†,‡,
  3. Peter J. Lee M.D.2,
  4. Ralph M. Zagha M.D.2,
  5. Jason Cain B.S.1,
  6. Mark Silverman M.D.3,
  7. John A. Libertino M.D.2,
  8. Ian C. Summerhayes Ph.D.1,§,*

Article first published online: 25 JUN 2003

DOI: 10.1002/cncr.11536

Issue

Cancer

Cancer

Volume 98, Issue 4, pages 737–744, 15 August 2003

Additional Information

How to Cite

Rieger-Christ, K. M., Mourtzinos, A., Lee, P. J., Zagha, R. M., Cain, J., Silverman, M., Libertino, J. A. and Summerhayes, I. C. (2003), Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection. Cancer, 98: 737–744. doi: 10.1002/cncr.11536

Author Information

  1. 1

    Cell and Molecular Biology Laboratory, Robert E. Wise M. D. Research and Education Institute, Burlington, Massachusetts

  2. 2

    Department of Urology, Lahey Clinic, Burlington, Massachusetts

  3. 3

    Department of Pathology, Lahey Clinic, Burlington, Massachusetts

  1. †

    Dr. Rieger-Christ and Dr. Mourtzinos were equal contributors to this work.

  2. ‡

    Dr. Arthur Mourtzinos is a Robert E. Wise Research Fellow.

  3. §

    Fax: (781) 744-2984

*Cell and Molecular Biology Laboratory, Robert E. Wise M. D. Research and Education Institute, Lahey Clinic, 31 Mall Road, Burlington, MA 01805

Publication History

  1. Issue published online: 1 AUG 2003
  2. Article first published online: 25 JUN 2003
  3. Manuscript Accepted: 22 APR 2003
  4. Manuscript Revised: 18 APR 2003
  5. Manuscript Received: 6 FEB 2003

Funded by

  • NIH Grant. Grant Number: R01-DK59400

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (92K)

REFERENCES

  • 1
    Presti JC Jr., Reuter VE, Galan T, Fair WR, Cordon-Cardo C. Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res. 1991; 51: 5405–5409.
  • 2
    Spruck CH III, Ohneseit PF, Gonzalez-Zulueta M, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res. 1994; 54: 784–788.
  • 3
    Richter J, Jiang F, Gorog JP, et al. Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res. 1997; 57: 2860–2864.
  • 4
    Cordon-Cardo C, Cote RJ, Sauter G. Genetic and molecular markers of urothelial premalignancy and malignancy. Scand J Urol Nephrol Suppl. 2000; 205: 82–93.
  • 5
    Zhang Z-T, Pak J, Shapiro E, Sun T-T, Wu X-R. Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. Cancer Res. 1999; 59: 3512–3517.
  • 6
    Zhang Z-T, Pak J, Huang H-Y, et al. Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene. 2001; 20: 1973–1980.
  • 7
    Sidransky D, Von Eschenbach A, Jones P, et al. The p53 gene is frequently altered in primary invasive bladder carcinoma and can be identified in urine sediment. Science. 1991; 252: 706–709.
  • 8
    Levesque P, Ramchurren N, Saini K, Joyce A, Libertino JA, Summerhayes IC. Screening of human bladder tumors and urine sediments for the presence of H-ras mutations. Int J Cancer. 1993; 55: 785–790.
    Direct Link:
  • 9
    Fitzgerald JM, Ramchurren N, Rieger KM, et al. Identification of H-ras mutations in urine sediments complements cytology in the detection of bladder tumors. J Natl Cancer Inst. 1995; 87: 129–133.
  • 10
    Mao L, Schoenberg MP, Scicchitano M, et al. Molecular detection of primary bladder cancer by microsatellite analysis. Science. 1996; 271: 659–662.
  • 11
    Kinoshita H, Okawa O, Kakehi Y, et al. Detection of telomerase activity in exfoliated cells in urine from patients with bladder cancer. J Natl Cancer Inst. 1997; 89: 724–730.
  • 12
    Chiang P-W, Schneider A, Borgnat S, et al. Molecular analysis of urine sediment for follow-up of urinary tract cancers. J Natl Cancer Inst. 2000; 92: 1779–1780.
  • 13
    Fliss MS, Usadel H, Caballero OL, et al. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science. 2000; 287: 2017–2019.
  • 14
    Van Rhijn BWG, Lurkin I, Kirkels WJ, Van der Kwast TH, Zwarthoff EC. Microsatellite analysis–DNA test in urine competes with cystoscopy in follow-up of superficial bladder cancer. A Phase II trial. Cancer. 2001; 92: 768–775.
    Direct Link:
  • 15
    Prescott JL, Montie J, Pugh TW, McHugh T, Veltri RW. Clinical sensitivity of p53 mutation detection in matched bladder tumor, bladder wash, and voided urine specimens. Cancer. 2001; 91: 2127–2135.
    Direct Link:
  • 16
    Sharp JD, Hausladen DA, Maher MG, Wheeler MA, Altieri DC, Weiss RM. Bladder cancer detection with urinary survivin, an inhibitor of apoptosis. Front Biosci. 2002; 7: 36–41.
  • 17
    Knowles MA. What can we do now: molecular pathology of bladder cancer. Br Med J. 2001; 54: 215–221.
  • 18
    Han K-R, Pantuck AJ, Belldegrun AS, Rao J-Y. Tumor markers for the early detection of bladder cancer. Front Biosci. 2002; 7: 19–26.
  • 19
    Naski MC, Wang Q, Xu J, Ornitz DM. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat Genet. 1996; 13: 233–237.
  • 20
    Webster MK, Donoghue DJ. FGFR activation in skeletal disorders: too much of a good thing. Trends Genet. 1997; 13: 178–182.
  • 21
    Cappellen D, De Oliveira C, Ricol D, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet. 1999; 23: 18–20.
  • 22
    Sibley K, Cuthbert-Heavens D, Knowles MA. Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma. Oncogene. 2001; 20: 686–691.
  • 23
    Kimura T, Suzuki H, Ohashi T, Asano K, Kiyota H, Eto Y. The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas. Cancer. 2001; 92: 2555–2561.
    Direct Link:
  • 24
    Billerey C, Chopin D, Aubriot-Lorton M-H, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol. 2001; 158: 1955–1959.
  • 25
    Van Rhijn RWG, Lurkin I, Radvanyi F, Kirkels WJ, Van der Kwast T, Zwarthoff EC. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res. 2001; 61: 1265–1268.
  • 26
    Wüchner C, Hilbert K, Zabel B, Winterpacht A. Human fibroblast growth factor receptor 3 gene (FGFR3): genomic sequence and primer set information for gene analysis. Hum Genet. 1997; 100: 215–219.
  • 27
    Holway AH, Rieger-Christ KM, Miner WR, et al. Somatic mutation of PTEN in vulvar cancer. Clin Cancer Res. 2000; 6: 3228–3235.
  • 28
    Van Rhijn BWG, Van Tilborg AAG, Lurkin I, et al. Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. Eur J Hum Genet. 2002; 10: 819–824.
  • 29
    Webster MK, Donoghue DJ. Enhanced signaling and morphological transformation by a membrane-localized derivative of the fibroblast growth factor receptor 3 kinase domain. Mol Cell Biol. 1997; 17: 5739–5747.
  • 30
    Van Rhijn BWG, Lurkin I, Chopin DK, et al. Combined microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine. Clin Cancer Res. 2003; 9: 257–263.
View Full Article (HTML) Get PDF (92K)